8-K: Elicio Therapeutics Annual Meeting Adjourned Due to Lack of Quorum, Reconvenes November 21

Elicio Therapeutics' annual stockholder meeting was adjourned due to a lack of quorum and will reconvene virtually on November 21, 2024.

Summary

• Elicio Therapeutics held its annual stockholder meeting on November 7, 2024, but it was adjourned because a quorum was not present.
• A majority of the shares represented by proxies had voted in favor of the proposals.
• The meeting will reconvene virtually on November 21, 2024, at 9:30 a.m. Eastern Time.
• Stockholders can attend the reconvened meeting by preregistering at www.viewproxy.com/ELTX/2024 using their previously provided virtual control number.
• The preregistration deadline is 11:59 p.m. Eastern Time on November 20, 2024.
• The record date for the reconvened meeting remains September 11, 2024.
• Previously submitted proxies will still be valid for the reconvened meeting.
• Stockholders can still vote or change their vote by proxy before the November 20 deadline.

Sentiment

Score: 4

Explanation: The adjournment of the annual meeting due to a lack of quorum is a negative event, but the company is taking steps to rectify the situation. The fact that a majority of proxies were in favor of the proposals is a positive sign.

Positives

• A majority of the proxies received were in favor of the proposals, indicating shareholder support.
• The company is taking steps to ensure all shareholders can participate in the reconvened meeting by providing a virtual option.

Negatives

• The annual meeting had to be adjourned due to a lack of a quorum, which could indicate low shareholder engagement or difficulties in achieving the required attendance.

Risks

• There is a risk that the reconvened meeting may also fail to achieve a quorum if shareholder participation does not improve.
• The need to adjourn and reconvene the meeting could cause delays in the company's decision-making processes.

Future Outlook

The company will proceed with the reconvened annual meeting on November 21, 2024, to address the proposals.

Management Comments

• The Annual Meeting was adjourned under Section 2.8 of the Amended and Restated Bylaws of the Company because a quorum of the holders of the Company's common stock was not present.
• At the time of the adjournment, a majority of the shares of Common Stock represented by proxies actually received by the Company had been voted in favor of each proposal that the Company intends to submit to stockholders at the Annual Meeting.

Industry Context

The adjournment of a shareholder meeting due to lack of quorum is not uncommon, but it does highlight the importance of shareholder engagement and participation in corporate governance.

Comparison to Industry Standards

• Many companies use virtual meetings to increase shareholder participation, which Elicio is doing for the reconvened meeting.
• The need to adjourn and reconvene a meeting is not ideal and can be seen as a sign of potential issues with shareholder engagement, which is a common challenge for many public companies.

Stakeholder Impact

• Shareholders are impacted by the delay of the annual meeting and need to take action to participate in the reconvened meeting.
• The company's management is impacted by the need to reschedule and manage the reconvened meeting.

Next Steps

• Stockholders need to preregister for the reconvened virtual meeting by November 20, 2024.
• The reconvened annual meeting will take place on November 21, 2024.
• The company will proceed with the proposals at the reconvened meeting.

Key Dates

Keywords

Annual Meeting, Stockholders, Quorum, Proxy Vote, Adjournment, Reconvened Meeting, Virtual Meeting, Shareholder, ELTX